Reviews
|
| Overcoming resistance to BRAF inhibition in BRAFmutated metastatic melanoma |
|
https://doi.org/10.18632/oncotarget.2602
|
| 10206-10221 |
|
| Regulation of ERBB3/HER3 signaling in cancer |
|
https://doi.org/10.18632/oncotarget.2655
|
| 10222-10236 |
Priority Research Papers
|
| Preclinical efficacy of sepantronium bromide YM155 in multiple myeloma is conferred by down regulation of Mcl1 |
|
https://doi.org/10.18632/oncotarget.2529
|
| 10237-10250 |
|
| Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γirradiation |
|
https://doi.org/10.18632/oncotarget.2500
|
| 10251-10270 |
Clinical Research Papers
|
| High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.2082
|
| 10271-10279 |
|
| Targeting hypoxiainducible factor1α HIF1α in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab |
|
https://doi.org/10.18632/oncotarget.2163
|
| 10280-10292 |
|
| CAMK2N1 inhibits prostate cancer progression through androgen receptordependent signaling |
|
https://doi.org/10.18632/oncotarget.2511
|
| 10293-10306 |
|
| Overexpression of plateletderived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.2537
|
| 10307-10317 |
Research Papers
|
| Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver |
|
https://doi.org/10.18632/oncotarget.2515
|
| 10318-10331 |
|
| The antitumor potential of Interleukin27 in prostate cancer |
|
https://doi.org/10.18632/oncotarget.1425
|
| 10332-10341 |
|
| Pharmacologic downregulation of EZH2 suppresses bladder cancer <em>in vitro</em> and <em>in vivo</em> |
|
https://doi.org/10.18632/oncotarget.1867
|
| 10342-10355 |
|
| PolyADPribosylation is involved in the epigenetic control of <em>TET1</em> gene transcription |
|
https://doi.org/10.18632/oncotarget.1905
|
| 10356-10367 |
|
| Failure of anti tumorderived endothelial cell immunotherapy depends on augmentation of tumor hypoxia |
|
https://doi.org/10.18632/oncotarget.2015
|
| 10368-10381 |
|
| p53 status as effect modifier of the association between pretreatment fasting glucose and breast cancer outcomes in non diabetic HER2 positive patients treated with trastuzumab |
|
https://doi.org/10.18632/oncotarget.2060
|
| 10382-10392 |
|
| Notch signaling drives multiple myeloma induced osteoclastogenesis |
|
https://doi.org/10.18632/oncotarget.2084
|
| 10393-10406 |
|
| Antitumor activity of S116836 a novel tyrosine kinase inhibitor against imatinibresistant FIP1L1PDGFRαexpressing cells |
|
https://doi.org/10.18632/oncotarget.2090
|
| 10407-10420 |
|
| H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.2126
|
| 10421-10433 |
|
| Mer590 a novel monoclonal antibody targeting MER receptor tyrosine kinase decreases colony formation and increases chemosensitivity in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.2142
|
| 10434-10445 |
|
| Medical treatment of orthotopic glioblastoma with transferrinconjugated nanoparticles encapsulating zoledronic acid |
|
https://doi.org/10.18632/oncotarget.2182
|
| 10446-10459 |
|
| Efficacy of dual PI3K and mTOR inhibitors <em>in vitro</em> and <em>in vivo</em> in acute lymphoblastic leukemia |
|
https://doi.org/10.18632/oncotarget.2260
|
| 10460-10472 |
|
| Thymidine phosphorylase activates NFκB and stimulates the expression of angiogenic and metastatic factors in human cancer cells |
|
https://doi.org/10.18632/oncotarget.2242
|
| 10473-10485 |
|
| Nicotinic acetylcholine receptors induce cKit ligand/Stem Cell Factor and promote stemness in an ARRB1/ βarrestin1 dependent manner in NSCLC |
|
https://doi.org/10.18632/oncotarget.2395
|
| 10486-10502 |
|
| Metformin and erlotinib synergize to inhibit basal breast cancer |
|
https://doi.org/10.18632/oncotarget.2391
|
| 10503-10517 |
|
| RNAseq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells |
|
https://doi.org/10.18632/oncotarget.2420
|
| 10518-10528 |
|
| AngioMatrix a signature of the tumor angiogenic switchspecific matrisome correlates with poor prognosis for glioma and colorectal cancer patients |
|
https://doi.org/10.18632/oncotarget.2470
|
| 10529-10545 |
|
| Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis |
|
https://doi.org/10.18632/oncotarget.2508
|
| 10546-10557 |
|
| Deacetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells |
|
https://doi.org/10.18632/oncotarget.2510
|
| 10558-10570 |
|
| SOX10 a novel HMGboxcontaining tumor suppressor inhibits growth and metastasis of digestive cancers by suppressing the Wnt/βcatenin pathway |
|
https://doi.org/10.18632/oncotarget.2512
|
| 10571-10583 |
|
| Androgen receptor promotes gastric cancer cell migration and invasion via AKTphosphorylation dependent upregulation of matrix metalloproteinase 9 |
|
https://doi.org/10.18632/oncotarget.2513
|
| 10584-10595 |
|
| Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5 |
|
https://doi.org/10.18632/oncotarget.2517
|
| 10596-10606 |
|
| Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR221 axis in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.2523
|
| 10607-10620 |
|
| Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.2524
|
| 10621-10635 |
|
| Downregulation of miRNA106b inhibits growth of melanoma cells by promoting G1phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein |
|
https://doi.org/10.18632/oncotarget.2527
|
| 10636-10649 |
|
| Regulation of NADPHdependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma cells by a photoactive NADPH analogue |
|
https://doi.org/10.18632/oncotarget.2525
|
| 10650-10664 |
|
| Inhibition of histone H3K79 methylation selectively inhibits proliferation selfrenewal and metastatic potential of breast cancer |
|
https://doi.org/10.18632/oncotarget.2496
|
| 10665-10677 |
|
| The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.2528
|
| 10678-10691 |
|
| Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells |
|
https://doi.org/10.18632/oncotarget.2530
|
| 10692-10708 |
|
| Regulation of the viability of <em>Nf1</em> deficient cells by PKC isoforms |
|
https://doi.org/10.18632/oncotarget.2531
|
| 10709-10717 |
|
| CCL5 promotes VEGFdependent angiogenesis by downregulating miR200b through PI3K/Akt signaling pathway in human chondrosarcoma cells |
|
https://doi.org/10.18632/oncotarget.2532
|
| 10718-10731 |
|
| Simultaneous targeting of PI3Kδ and a PI3Kδdependent MEK1/2Erk1/2 pathway for therapy in pediatric Bcell acute lymphoblastic leukemia |
|
https://doi.org/10.18632/oncotarget.2533
|
| 10732-10744 |
|
| Resveratrol potentiates the <em>in vitro</em> and <em>in vivo</em> antitumoral effects of curcumin in head and neck carcinomas |
|
https://doi.org/10.18632/oncotarget.2534
|
| 10745-10762 |
|
| Fas signaling promotes chemoresistance in gastrointestinal cancer by upregulating Pglycoprotein |
|
https://doi.org/10.18632/oncotarget.2498
|
| 10763-10777 |
|
| Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer |
|
https://doi.org/10.18632/oncotarget.2502
|
| 10778-10790 |
|
| Induction of a specific CD8+ Tcell response to cancer/testis antigens by demethylating pretreatment against osteosarcoma |
|
https://doi.org/10.18632/oncotarget.2505
|
| 10791-10802 |
|
| Oct4 and nanog promote the epithelialmesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients |
|
https://doi.org/10.18632/oncotarget.2506
|
| 10803-10815 |
|
| miR145 inhibits tumor growth and metastasis by targeting metadherin in highgrade serous ovarian carcinoma |
|
https://doi.org/10.18632/oncotarget.2522
|
| 10816-10829 |
|
| A novel drug discovery strategy: Mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NFκB pathways |
|
https://doi.org/10.18632/oncotarget.2521
|
| 10830-10839 |
|
| CDKL2 promotes epithelialmesenchymal transition and breast cancer progression |
|
https://doi.org/10.18632/oncotarget.2535
|
| 10840-10853 |
|
| Stromal TGFβ signaling induces AR activation in prostate cancer |
|
https://doi.org/10.18632/oncotarget.2536
|
| 10854-10869 |
|
| Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21 p27 and p53 in cervical carcinomas |
|
https://doi.org/10.18632/oncotarget.2539
|
| 10870-10885 |
|
| The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway |
|
https://doi.org/10.18632/oncotarget.2540
|
| 10886-10900 |
|
| Downregulation of BRCA1BRCA2containing complex subunit 3 sensitizes glioma cells to temozolomide |
|
https://doi.org/10.18632/oncotarget.2543
|
| 10901-10915 |
|
| Angiostatic tumor inflammatory and antitumor effects of CXCL44770 and CXCL4L14770 in an EGFdependent breast cancer model |
|
https://doi.org/10.18632/oncotarget.2538
|
| 10916-10933 |
|
| Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo |
|
https://doi.org/10.18632/oncotarget.2541
|
| 10934-10948 |
|
| An NCR1based chimeric receptor endows Tcells with multiple antitumor specificities |
|
https://doi.org/10.18632/oncotarget.1919
|
| 10949-10958 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
